Skip To Main Content
Xiongying Jiang on Muck Rack

Xiongying Jiang

As seen in: Nature, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiongying

Contact Xiongying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study

|
By Jiongliang Wang, Yimin Zhang, Xiongying Jiang, Song Chen, Jie Xu, Xintong Wu, Qifeng Chen, Yue Hu, Yujia Song, Yunan Zhang, Ming Zhao, Ning Lyu, Junzhe Yi, Suixing Zhong, Genjun Tan
| Nature Verified
Abstract Hepatocellular carcinoma (HCC) patients with Vp4 portal vein tumor thrombus (PVTT) have a poor prognosis and are underrepresented in global clinical trials. We conducted a single-arm phase 2 study (DurHope) enrolling 30 patients with Vp3/4 PVTT receiving durvalumab plus hepatic arterial infusion therapy (HAIC) of FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin) as first-line treatment.
Open in Who Shared Issue with article?

Efficiency and safety of HAIC combined with lenvatinib and PD-1 inhibi

|
By Song Chen, Ning WANG, Yi Xiao, Xiongying Jiang
| Dove Medical Press
Introduction According to 2022 statistics, liver cancer ranks as the sixth most common malignancy and the third leading cause of cancer-related death globally.1 Hepatocellular carcinoma (HCC) constitutes the majority of liver cancer cases. Due to the absence of distinct early-stage symptoms and inadequate surveillance in high-risk populations, most HCC cases are diagnosed at an advanced stage, resulting in a poor prognosis—particularly in the presence of extrahepatic metastases.
Open in Who Shared Issue with article?
See all 2 articles